29-May-2025 6:30 AM CST - Business Wire Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Jefferies Global Healthcare Conference June 4-5, 2025 Type: Fireside Chat Presentation Date/Time: June 4, 2025, 9:20 a.m. EDT 46th Annual Goldman Sachs Global Healthcare Conference June 9-11, 2025 Type: Fireside Chat Presentation Date/Time: June 9, 2025, 2:00 p.m. EDT Presentation webcasts may be accessed on the Even
12-May-2025 3:01 PM CST - Business Wire Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards our long-term goal of developing and ultimately commercializing new innovative medicines for millions of patients. We
7-May-2025 6:30 AM CST - Business Wire Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events an
30-Apr-2025 3:01 PM CST - Business Wire Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately t
10-Feb-2025 3:01 PM CST - Business Wire Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which w
22-Jan-2025 3:00 PM CST - Business Wire Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approxim
26-Nov-2024 3:00 PM CST - Business Wire Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM technology. We have the potential to impact the lives of millions
26-Nov-2024 6:00 AM CST - Business Wire Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs. The agreement will add meaningfully to S
5-Nov-2024 6:30 AM CST - Business Wire Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two
29-May-2025 6:30 AM CST - Business Wire Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Jefferies Global Healthcare Conference June 4-5, 2025 Type: Fireside Chat Presentation Date/Time: June 4, 2025, 9:20 a.m. EDT 46th Annual Goldman Sachs Global Healthcare Conference June 9-11, 2025 Type: Fireside Chat Presentation Date/Time: June 9, 2025, 2:00 p.m. EDT Presentation webcasts may be accessed on the Even
12-May-2025 3:01 PM CST - Business Wire Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards our long-term goal of developing and ultimately commercializing new innovative medicines for millions of patients. We
7-May-2025 6:30 AM CST - Business Wire Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events an
30-Apr-2025 3:01 PM CST - Business Wire Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately t
10-Feb-2025 3:01 PM CST - Business Wire Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which w
22-Jan-2025 3:00 PM CST - Business Wire Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approxim
26-Nov-2024 3:00 PM CST - Business Wire Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM technology. We have the potential to impact the lives of millions
26-Nov-2024 6:00 AM CST - Business Wire Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs. The agreement will add meaningfully to S
5-Nov-2024 6:30 AM CST - Business Wire Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two
